SCHEMBL280382

SCHEMBL280382

Cc1ccc(C(=O)CS(=O)(=O)c2cncnc2)s1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 3/20 0.45
DAO P14920 1/20 0.41
ALDH1A1 P00352 6/20 0.38
POLB P06746 2/20 0.38
HPGD P15428 1/20 0.38
CASP3 P42574 1/20 0.38
SENP8 Q96LD8 1/20 0.38
SENP7 Q9BQF6 1/20 0.38
SENP6 Q9GZR1 1/20 0.38
KMT2A Q03164 4/20 0.38
RAB9A P51151 4/20 0.38
NPC1 O15118 3/20 0.38
MEN1 O00255 3/20 0.38
TDP1 Q9NUW8 1/20 0.37
RECQL P46063 1/20 0.36
TAS1R3 Q7RTX0 1/20 0.35
TAS1R1 Q7RTX1 1/20 0.35
KDM4E B2RXH2 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL279741 0.84 HSD11B1 (0.49) HSD11B1DAOALDH1A1POLBHPGD
SCHEMBL279755 0.75 HSD11B1 (0.40) HSD11B1DAOALDH1A1POLBHPGD
SCHEMBL280137 0.69 ADORA2A (0.44) DAOALDH1A1POLBHPGDCASP3
SCHEMBL15979700 0.69 DAO (0.61) DAOALDH1A1POLBHPGDCASP3
SCHEMBL4140001 0.67 DAO (0.59) DAOALDH1A1POLBHPGDCASP3
SCHEMBL9372669 0.67 DAO (0.59) DAOALDH1A1POLBHPGDCASP3
SCHEMBL6394534 0.66 GSK3B (0.62) DAOALDH1A1POLBHPGDCASP3
SCHEMBL22721115 0.66 DAO (0.57) DAOALDH1A1POLBHPGDCASP3
SCHEMBL14228434 0.66 DAO (0.57) DAOALDH1A1POLBHPGDCASP3
SCHEMBL3926030 0.66 GSK3B (0.66) DAOALDH1A1POLBHPGDCASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL HSD11B1 3197/4885DAO 1673/4885ALDH1A1 2047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.